Randomized Trialhigh evidence
Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial.
Menopause (New York, N.Y.)·April 14, 2026·PMID 41979542
Why it mattersVasomotor symptoms affect quality of life in menopause, and non-hormonal options are needed for women who cannot or prefer not to use hormone therapy. GS1-144 offers a targeted neurokinin 3 receptor antagonist approach with efficacy and safety data in an Asian population, expanding therapeutic choices.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled